JPRN-jRCT1080225085已完成Unknown
Post-marketing surveillance of DIACOMIT (Capsule: 250 mg or 500 mg, Powder for Oral Suspension: 250 mg or 500 mg)
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All patients who start receiving DIACOMIT Tablet during the registration period.
排除标准
- •Patients with a previous history of hypersensitivity to the ingredients of DIACOMIT.
研究者
相似试验
已完成
不适用
Post-marketing surveillance of Vadadustat in patients with anemia in chronic kidney disease for long-term efficacy and safetyRenal anemiaJPRN-UMIN000042349Mitsubishi Tanabe Pharma Corporation2,000
未知
Unknown
Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-investigation of the clinical condition in patients with changing from botulinum toxin type Acervical dystoniaJPRN-jRCT1080222128Eisai Co., Ltd.150
已完成
Unknown
Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-Investigation of the clinical condition and safety in patients with cervical dystoniacervical dystoniaJPRN-jRCT1080222127Eisai Co., Ltd.
招募中
Unknown
All case study of Lenvima Capsulenresectable thyroid cancerJPRN-jRCT1080222856Eisai Co., Ltd.400
已完成
不适用
Post-marketing surveillance for refractory uveoretinitis associated with Behcet's disease under Remicade treatmentBehcet's diseaseJPRN-UMIN000027733Mitsubishi Tanabe Pharma Corporation100